Anebulo Pharmaceuticals Administers First Doses in Selonabant Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 25 2025
0mins
Phase 1 Study Initiation: Anebulo Pharmaceuticals has commenced its Phase 1 single ascending dose study of intravenous selonabant in healthy young adults.
Funding Support: The study is being supported by a collaborative grant from the National Institute on Drug Abuse.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like ANEB with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on ANEB
About ANEB
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous administration. Selonabant is intended to rapidly reverse the negative effects of cannabis-induced toxicity and reduce time to recovery. It is also prioritizing the advancement of a selonabant intravenous (IV) formulation as a potential treatment for pediatric patients with cannabis-induced CNS depression.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Anebulo Completes Voluntary Tender Offer for 300,000 Shares
- Tender Offer Results: Anebulo Pharmaceuticals announced the final results of its voluntary tender offer to repurchase 300,000 shares at $3.50 each, totaling approximately $1.05 million, reflecting the company's commitment to shareholders and a significant premium over market prices.
- Oversubscription: The tender offer received a total of 4,907,881 shares tendered, indicating strong investor confidence in the company's future, with 300,000 shares accepted on a pro-rata basis, ensuring benefits for smaller shareholders.
- Shareholder Structure Optimization: By executing this tender offer, Anebulo successfully reduced the number of shareholders, enhancing shareholder concentration, which may facilitate future capital operations and corporate governance.
- Clinical Research Advancement: Anebulo is prioritizing the intravenous formulation of selonabant for pediatric acute cannabis-induced toxicity treatment, aiming for a faster approval timeline, demonstrating the company's strategic shift in drug development.
Continue Reading
UniFirst Corp (UNF) Receives $5.2B Acquisition Proposal from Cintas (CTAS) at 64% Premium
- Acquisition Proposal: Cintas Corporation has proposed to acquire UniFirst for $275 per share in cash, valuing the company at approximately $5.2 billion, which represents a 64% premium over its 90-day average closing price, indicating strong confidence in UniFirst's future growth potential.
- Market Reaction: This news has driven UniFirst's stock price up by 18.6%, reflecting investor optimism regarding the acquisition deal, and it may also attract interest from other potential buyers, further intensifying market competition.
- Industry Impact: The acquisition proposal could reshape the uniform and workwear industry landscape, as Cintas aims to enhance its market share and service capabilities by integrating UniFirst's resources and customer base.
- Strategic Significance: Cintas's acquisition intent not only underscores its focus on industry consolidation but also has the potential to achieve long-term business growth and profitability enhancement through an expanded product line and service offerings.
Continue Reading